Abstracts tagged "B-Lymphocyte"

Abstract Number: 0775 • ACR Convergence 2022
The Distribution and Frequency of Autoreactive B Cells Are Altered in Autoimmune Patients After TNF Inhibitor Treatment
Tam Quach¹, Meggan Mackay², Cynthia Aranow² and Anne Davidson², ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of new autoantibodies and secondary autoimmunity is a common and significant side effect of TNF inhibitors (TNFi) which are widely used to…
Abstract Number: 1713 • ACR Convergence 2022
Bank1 Signaling Shapes the Gut Microbiota Composition by Controlling the Gut Mucosal B-cell Response in Lupus
Georgina Galicia-Rosas, María Botía Sánchez, Daniel Toro-Domínguez, Lorena Albadalejo and Marta Alarcon-Riquelme, Center for Genomics and Oncological Research (GENYO), Granada, Spain
Background/Purpose: Mucosa-associated commensal bacteria have been shown to be involved in the pathogenesis of systemic lupus erythematosus (SLE). However, its exact role remains to be…
Abstract Number: 0011 • ACR Convergence 2022
B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice
Kristina Ottens, Jalyn Schneider and Anne Satterthwaite, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by autoantibodies (autoAbs) against nucleic acid containing antigens. These antibodies form immune complexes that promote inflammation and cause organ…
Abstract Number: 0778 • ACR Convergence 2022
TNF Inhibitors Display a Modulatory Effect on Serological and Cellular Vaccine Response in Patients with Chronic Inflamatory Diseases
Ulf Geisen¹, Ruben Rose², Dennis Berner³, Hayley Reid³, Jan Schirmer⁴, Florian Tran⁵, Sascha Gerdes⁶, Stefan Schreiber⁷, Andi Krumbholz¹, Petra Bacher⁷ and Bimba Hoyer¹, ¹UKSH Kiel, Kiel, Germany, ²Dep Infectiology UKSH Kiel, Kiel, Germany, ³Dep Rheumatology and clinical Immunology, UKSH Kiel, Kiel, Germany, ⁴University Medical Center Schleswig-Holstein, Kiel, Germany, ⁵Medical Department, UKSH Kiel, Kiel, Germany, ⁶Dermatology, UKSH Kiel, Kiel, Germany, ⁷Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany
Background/Purpose: Background: The ongoing pandemic is an immunological challenge when using immune modulating drugs. The mRNA vaccines against SARS-CoV-2 are safe and efficient in most…
Abstract Number: 1715 • ACR Convergence 2022
Ezh2 Knockout in B Cells Impairs Plasmablast Differentiation and Ameliorates Lupus-like Disease in MRL/lpr Mice
Xiaoqing Zheng¹, Mikhail Dozmorov², Colleen Strohlein¹, Sheldon Bastacky¹ and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Virginia Commonwealth University, Richmond, VA
Background/Purpose: Enhancer of zeste homolog 2 (EZH2) has been shown to regulate early B cell development and the differentiation of antibody secreting cells (ASCs). We…
Abstract Number: 0460 • ACR Convergence 2021
Single-cell Profiling of B and T Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion
Nida Meednu¹, Aaron Wagner², Garett Dunlap³, Fan Zhang⁴, Anna Helena Jonsson⁵, Kevin Wei⁵, Paul Utz⁶, William Robinson⁷, Holden Maecker⁷, Judith James⁸, Joel Guthridge⁸, S. Louis Bridges, Jr.⁹, Vivian Bykerk⁹, Laura Donlin⁹, Susan Goodman⁹, Edward DiCarlo⁹, Christopher Ritchlin¹⁰, Darren Tabechian², James Lederer¹¹, Ellen Gravallese¹², Mandy McGeachy¹³, Gary Firestein¹⁴, David Boyle¹⁵, Peter Gregersen¹⁶, Diane Horowitz¹⁷, Harris Perlman¹⁸, Arthur Mandelin¹⁸, Joan Bathon¹⁹, Laura Geraldino-Pardilla¹⁹, Laura Hughes²⁰, V. Michael Holers²¹, Kevin Deane²², Larry Moreland²¹, Andrew Filer²³, Costantino Pitzalis²⁴, Lindsy Forbess²⁵, Ami Ben-artzi²⁶, Karen Salomon-Escoto²⁷, Soumya Raychaudhuri⁵, Michael Brenner²⁸, Deepak Rao⁵, Andrew McDavid², Jennifer Anolik¹ and Accelerating Medicines Partership (AMP) RA/SLE Network²⁹, ¹University of Rochester Medical center, Rochester, NY, ²University of Rochester, Rochester, NY, ³Harvard University, Somerville, MA, ⁴Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Stanford University, Stanford, CA, ⁷Stanford University, Palo Alto, CA, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹¹Brigham and Women's Hospital and Harvard Medical School, Millis, MA, ¹²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹³University of Pittsburgh, Pittsburgh, PA, ¹⁴University of California San Diego, San Diego, CA, ¹⁵University of California San Diego, La Jolla, CA, ¹⁶The Feinstein Institute for Medical Research, Larchmont, NY, ¹⁷Northwell Health, Jericho, NY, ¹⁸Northwestern University, Chicago, IL, ¹⁹Columbia University, New York, NY, ²⁰University of Alabama at Birmingham, Birmingham, AL, ²¹University of Colorado, Denver, CO, ²²University of Colorado Denver, Denver, CO, ²³University of Birmingham, Birmingham, United Kingdom, ²⁴Queen Mary University of London, London, United Kingdom, ²⁵Cedars-Sinai Medical Center, Los Angeles, CA, ²⁶Cedars-Sinai Medical Center, Beverly Hills, CA, ²⁷University of Massachusetts Medical School, Shrewsbury, MA, ²⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁹Brigham and Women's Hospital, Everett, MA
Background/Purpose: B cell and T cell activation pathways in the synovium are an incompletely understood feature of rheumatoid arthritis. In this study, utilizing single cell…
Abstract Number: 0982 • ACR Convergence 2021
B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach
Aurelie Najm¹, Shrutii Sarda², Michelle Toro³, Loni Pickle³, Stephanie Ostresh³, Fraser Morton⁴, Geoffrey Lowman³, Andrew Felton⁵ and Carl Goodyear⁴, ¹Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, South San Francisco-CA, United States, San Francisco, ³Clinical Sequencing Division, Specialty Diagnostics Group, Thermo Fisher Scientific, Carlsbad, CA, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵VP, Platforms, Research & Applied, Specialty Diagnostics Group, South San Francisco, CA
Background/Purpose: The adaptive immune system plays a central role in Rheumatoid Arthritis (RA) pathogenesis. Moreover, the composition of the B cell repertoire and its perturbation…
Abstract Number: 0986 • ACR Convergence 2021
Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
Thomas Dörner¹, Simon J Bowman², Robert Fox³, Xavier Mariette⁴, Athena Papas⁵, Thomas Grader-Beck⁶, Ben A Fisher², Filipe Barcelos⁷, Salvatore De Vita⁸, Hendrik Schulze-Koops⁹, Robert Moots¹⁰, Guido Junge¹¹, Janice Woznicki¹², Monika Sopala¹¹, Wen-Lin Luo¹² and Wolfgang Hueber¹¹, ¹Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, ²Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Scripps Memorial Hospital and Research Institute, San Diego, CA, ⁴Université Paris- Saclay, Rheumatology, Paris, France, ⁵Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁶Johns Hopkins University, Baltimore, MD, ⁷Instituto Português de Reumatologia, Lisbon, Portugal, ⁸Division of Rheumatology, DAME, University Hospital of Udine, Udine, Italy, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹⁰Academic Rheumatology Department, Aintree University Hospital, Liverpool, United Kingdom, ¹¹Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune disease affecting excretory glands and characterized by B-cell hyperactivity. Ianalumab (VAY736) is a human monoclonal antibody to B-cell…
Abstract Number: 1224 • ACR Convergence 2021
Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab
Samuel Bitoun¹, Bineta Ly², Signe Hässler³, Audrey Paoletti⁴, Aude Gleizes⁵, Salima Hacein-Bey⁵, Philippe Bröet³, Marc Pallardy⁶ and Xavier Mariette⁷, ¹Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, ²INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, ³CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, ⁴INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, ⁵Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, ⁶Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, ⁷Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
Abstract Number: 1251 • ACR Convergence 2021
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Borja Hernandez-Breijo¹, Ioannis Parodis², Chamaida Plasencia-Rodríguez³, Mariana Díaz-Almirón⁴, Ana Martínez-Feito⁵, Marta Novella-Navarro³, Dora Pascual-Salcedo¹ and Alejandro Balsa³, ¹Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ³Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: The latest breakthroughs in the pathophysiology of rheumatoid arthritis (RA) highlighted the activation of B cells as a trigger of the joint flare initiation…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
Abstract Number: 0002 • ACR Convergence 2021
Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
Sarah Pringle¹, Bas Berkhof¹, Martha S. van Ginkel², Silvia Liefers¹, Bert van der vegt², Fred Spijkervet², Hendrika Bootsma¹, Arjan Vissink¹ and Frans Kroese¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Patients with Sjögren’s syndrome (SS) suffer from significantly reduced saliva production. Saliva is important for oral health. A careful of sodium, chloride, potassium and…
Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].